VKVikash Khandelia

Vikash Khandelia

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Vikash Khandelia has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A multicenter prospective real-world cohort study of direct oral anticoagulant use for venous thromboembolism prophylaxis in nephrotic syndrome

    by Priti Meena, Nitin Kumar, Sandip Kumar Panda, Sharon Kandari, Ganesh Srinivasa Prasad, Vinant Bhargava, Vikash Khandelia, Prashant Malviya, Nikunj Kishore Rout, Paromita Das, et al.

    Nephrotic syndrome (NS), especially when associated with severe hypoalbuminia, confers a high risk of venous thromboembolism (VTE). While low-molecular-wei

  • Open Access

    A Multicentric prospective Real-World Experience of Direct Oral Anticoagulants use in prophylaxis of Venous Thromboembolism in Nephrotic syndrome

    by Priti Meena, Nitin Kumar, Sandip Kumar Panda, Sharon Kandari, Ganesh Srinivasa Prasad, Vinant Bhargava, Vikash Khandelia, Prashant Malviya, Nikunj Kishore Rout, Paromita Das, et al.

    Introduction : Patients with nephrotic syndrome (NS), particularly with severe hypoalbuminia are at significantly increased risk for venous thromboembolism (VTE). Although vitamin K antagonists (VKAs) have traditionally been used for prophylaxis. Evidence supporting direct oral anticoagulants (DOACs) for primary prophylaxis in NS remains scarce, with a lack of prospective real-world data. Methods : We conducted a prospective multicentric cohort study across eight tertiary centers in India, enrolling adults (≥ 18 years) with NS and severe hypoalbuminemia (albumin < 2.4 g/dL for Membranous nephropathy; <2.0 g/dL for other etiologies). All patients received apixaban 5 mg once daily as primary VTE prophylaxis until albumin levels improved beyond 2.4 g/dL. The primary composite outcome included VTE occurrence and major or clinically significant bleeding events. Patients were followed until anticoagulation discontinuation. Results : A total of 212 patients were analyzed (mean age 36.9 ± 14.0 years, 52% male). Median proteinuria was 9.0 g/day and mean serum albumin 1.68 ± 0.49 g/dL; mean serum creatinine was 1.5 ± 0.54 mg/dL. Most patients were categorized as low (80%) or intermediate (20%) bleeding risk by GN tool. Membranous nephropathy was the most common etiology (45%). Immunosuppressive therapy included corticosteroids (81%), rituximab (25.9%), and cyclophosphamide (28.3%). The mean duration of apixaban therapy was 3 months. No venous or arterial thromboembolic events occurred, and minor bleeding was observed in 4 patients (3.5%), all resolving without transfusion or hospitalization. Overall apixaban was well tolerated. Conclusion : This large multicenter prospective study showed that apixaban prophylaxis appears safe, well-tolerated, and potentially effective in preventing VTE among high-risk NS patients. Larger randomized trials are needed to validate findings and optimize dosing, but current data support the rational integration of DOACs into NS thromboprophylaxis protocols.

  • A Retrospective Cohort Study on the Risk of Kidney Disease in HIV Positive Individuals Receiving Tenofovir Based Regimens

    by Vikash Khandelia, Umashankar Nama, Ashok Mahavar, Anjali Rathore

    Introduction: Exposure to Tenofovir often leads to the development of some irreversible high risk for kidney disease events. In Human Immunodeficiency Virus (HIV) patients, the prolonged treatment with tenofovir use frequently causes mildto-moderate nephrotoxicity. Hence, there is a need to further investigate the efficacy and the adverse effects associated with tenofovir use to combat the decreased morbidity and mortality associated with the declined kidney function. Aim: To investigate the risk of kidney disease associated with tenofovir use. Materials and Methods: A retrospective study was conducted at the tertiary care centre in northern India, from August 2009 to January 2017 and analysed during January to May 2021. The patients with HIV infection who were administered Tenofovir, Lamivudine and Efavirenz (TLE) and Zidovudine, Lamivudine and Nevirapine (ZLN) were included.The patients were divided into two group based on the TLE and ZLN regimen they received. These patients were on a regular follow-up for six months. The data was assessed on the basis of serum creatinine and estimated Glomerular Filtration Rate (eGFR) (using Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation), body weight and Cluster of Differentiation (CD4) count. Results: Out of 703 patients, 364 patients were administered with TLE, while 339 patients received ZLN. In both the groups, the number of patients were between the age 21-40 years was significantly higher, followed by patients between the age 41- 60 years. The mean weight and CD4 count of the patients in both the groups significantly increased with the progression of time (p0.05. The mean eGFR level was significantly lowered in TLE group (112.2 mL/ min/1.73 m2 ) compared to ZLN group (123.5 mL/min/1.73m2 ) at 24-months follow-up (p<0.001). Conclusion: Overall results demonstrate that increasing exposure to tenofovir was associated with a higher incidence of CKD. The serum creatinine levels were comparable between the TLE and ZLN group.